What Do We Know About MK-677?
MK-677 is also known as ibutamoren. It is an investigational compound that stimulates the release of growth hormone. Researchers have studied its effects on growth hormone (GH), insulin-like growth factor 1 (IGF-1), and body composition.
MK-677 has gained attention in discussions about muscle mass, recovery, and age-related changes. However, its research record requires a closer look beyond common claims.
Human trials show that MK-677 can increase GH and IGF-1 levels. Some studies also report changes in fat-free mass, appetite, and glucose regulation. One should keep in mind that increased hormone levels do not automatically produce better strength, physical function, or long-term health.
This article reviews what scientific studies tell us about MK-677, its proposed mechanism, potential effects, and known safety concerns.
What Is MK-677 or Ibutamoren?
MK-677 is an orally active growth hormone secretagogue. It stimulates growth hormone release system of the body rather than supplying synthetic growth hormone directly.
One important distinction is that MK-677 is not a peptide or a SARM. It is a non-peptide compound that acts as a ghrelin receptor agonist. Researchers developed it to study the regulation of growth hormone and related biological processes.
MK-677 interacts with the growth hormone secretagogue receptor type 1a (GHS-R1a). This receptor also responds to ghrelin, a hormone involved in appetite regulation and other physiological functions.
By activating this receptor, MK-677 stimulates the release of growth hormone from the pituitary gland. Growth hormone can then increase the production of IGF-1, mainly in the liver and other tissues.
MK-677: How Does it Work?
MK-677 acts on the ghrelin receptor. This receptor is also known as GHS-R1a. It plays an important role in appetite regulation and growth hormone release.
Its proposed mechanism involves several connected steps:
Ghrelin receptor activation: MK-677 binds to and activates GHS-R1a.
Growth hormone release: Receptor activation stimulates growth hormone secretion from the pituitary gland.
IGF-1 production: Increased growth hormone can stimulate IGF-1 production in the liver and other tissues.
Downstream signaling: IGF-1 interacts with its receptors and activates pathways involved in cell growth, metabolism, and tissue maintenance.
This process differs from direct growth hormone administration. MK-677 stimulates the body's own GH release system, while recombinant growth hormone supplies the hormone itself.
However, changes in GH and IGF-1 levels do not prove that MK-677 improves muscle strength, athletic performance, or recovery.
What Does Human Research Tell Us About MK-677?
Researchers have studied MK-677 in several human trials. These studies provide useful information about hormone levels, body composition, appetite, and metabolic effects.
MK-677 and Growth Hormone Levels
A 1996 randomized, double-blind, placebo-controlled study examined MK-677 in 32 healthy adults aged 64 to 81.
Researchers tested oral doses of 2 mg, 10 mg, and 25 mg across short treatment periods. The results showed dose-related increases in growth hormone secretion.
At the 25 mg level, average 24-hour GH concentrations increased by approximately 97% after two weeks. IGF-1 levels also increased during the study.
However, researchers also observed higher fasting blood glucose levels. This finding raised concerns about possible effects on glucose regulation.
MK-677 and Body Composition
One of the most discussed human studies appeared in 2008 in the Annals of Internal Medicine.
This randomized, double-blind trial included 65 healthy adults aged 60 to 81. Participants received MK-677 or a placebo during a two-year study period.
After 12 months, the MK-677 group showed an average increase of 1.1 kg in fat-free mass. The placebo group showed an average decrease of 0.5 kg.
However, the study found no significant improvement in strength or physical function. It also found no significant reduction in total body fat or abdominal visceral fat.
Participants who received MK-677 also experienced increased appetite, mild lower-limb swelling, and changes in blood glucose regulation.
This study highlights an important difference between body composition and physical performance. An increase in fat-free mass does not necessarily mean greater strength or better daily function.
MK-677 and Fat-Free Mass in Obese Adults
A 1998 randomized, double-blind study examined MK-677 in 24 obese men aged 18 to 50.
Participants received 25 mg of MK-677 or a placebo daily for eight weeks. Researchers reported an increase of approximately 40% in IGF-1 levels among participants who received MK-677.
Fat-free mass also increased during the study. However, total body fat and visceral fat did not show significant reductions.
The researchers also reported impaired glucose homeostasis during oral glucose tolerance testing.
These findings do not establish MK-677 as a weight-loss compound. They also show why changes in lean mass should not be confused with proven improvements in body composition.
MK-677 vs. Growth Hormone: What Is the Difference?
Feature | MK-677 (Ibutamoren) | Recombinant Growth Hormone |
Compound type | Non-peptide small molecule | Recombinant protein hormone |
Main action | Activates the ghrelin receptor | Supplies growth hormone directly |
GH release | Stimulates endogenous GH secretion | Does not depend on pituitary release |
IGF-1 | Can increase IGF-1 levels | Can increase IGF-1 levels |
Administration studied | Oral | Usually injection |
FDA status | Not FDA-approved | Certain products have FDA-approved indications |
These compounds are not interchangeable. Their mechanisms, clinical uses, and regulatory status differ.
Potential Side Effects of MK-677
MK-677 has the potential to impact various hormonal and metabolic pathways. Important concerns were identified during human clinical trials and during FDA safety reviews.
Reported/identified side effects include:
Increased Appetite – Some individuals experienced increased appetite during clinical trials.
Water Retention – Some individuals experienced fluid build up and swelling, particularly in the lower limbs.
Increased Blood Sugar – Some studies found that blood sugar levels were higher when fasting.
Reduced Insulin Sensitivity – Research found that insulin sensitivity was impacted.
Muscle Aches and Joint Pain – Clinical studies found that some individuals would experience muscle pain and joint issues.
Fatigue and Shortness of Breath – Some clinical safety reports found that this occurred.
Cardiovascular Concerns – The FDA identified reports of congestive heart failure in older individuals recovering from hip fracture.
The FDA also identified concerns regarding hyperglycaemia, increased liver enzymes, oedema, and fluid overload during its 2024 review. It is important to interpret these results carefully, as risks may differ between different populations.
There is currently not enough evidence from studies to determine the risks of long-term exposure for different age groups.
Is MK-677 Approved by the FDA?
No. MK-677 (ibutamoren) is not approved by the FDA for human use.
During its October 2024 Pharmacy Compounding Advisory Committee meeting, the FDA reviewed ibutamoren mesylate. It was found that there wasn’t enough evidence to support its use for many indications, including growth hormone deficiency, osteoporosis, sarcopenia, obesity, and Alzheimers.
Safety concerns were also identified, including impacts on glucose regulation, water retention, increased liver enzymes, and cardiovascular events.
In September 2025, the FDA issued a warning to consumers regarding a children’s growth product containing ibutamoren without labelling it. They stated that this was not an approved ingredient and that there were concerns regarding potential negative side effects.
In June 2026, Australia’s Therapeutic Goods Administration also reported that some unapproved MK-677 capsules contained an undisclosed anabolic steroid. This demonstrates the risk associated with products that aren’t reliably manufactured.
FAQs
1. Is MK-677 a peptide?
No. MK-677 is a non-peptide compound that activates the ghrelin receptor. It is often discussed alongside peptides because of its effects on growth hormone release.
2. Is MK-677 a SARM?
No. MK-677 is not a selective androgen receptor modulator. It acts on the ghrelin receptor rather than the androgen receptor.
3. Does MK-677 increase growth hormone?
Human clinical trials show that MK-677 can increase growth hormone secretion. Several studies also report higher circulating IGF-1 levels.
4. Does MK-677 increase muscle mass?
Some human studies report increases in fat-free mass. However, available research has not established consistent improvements in muscle strength or physical function.
5. Does MK-677 cause water retention?
Yes. Fluid retention and mild swelling appeared in human clinical studies. The FDA has also identified edema and fluid overload as safety concerns.
6. Is MK-677 approved for bodybuilding?
No. MK-677 is not FDA-approved for bodybuilding, muscle growth, or athletic performance. Its use for these purposes lacks established clinical support.
7. Is long-term MK-677 use safe?
Current evidence cannot establish its long-term safety. More research is needed to understand its metabolic, cardiovascular, and other potential risks.
Conclusion: What Do We Really Know About MK-677?
MK-677 has demonstrated clear effects on growth hormone and IGF-1 levels in human clinical studies. Research also suggests possible changes in fat-free mass and bone turnover.
However, these findings come with important limitations. Increased fat-free mass has not consistently translated into better strength or physical function. Studies have also identified concerns about blood glucose, insulin sensitivity, appetite, and fluid retention.
The available evidence does not establish MK-677 as a proven muscle-building, fat-loss, or recovery compound. Its long-term safety also remains uncertain.
For now, MK-677 remains an investigational compound rather than an FDA-approved treatment.